scholarly journals RNA Drug Discovery: Developing computational methods to predict antiterminator-targeted T-box riboswitch inhibitors

Author(s):  
Ali H. Aldhumani ◽  
J.V. Hines
2013 ◽  
Vol 66 (1) ◽  
pp. 334-395 ◽  
Author(s):  
Gregory Sliwoski ◽  
Sandeepkumar Kothiwale ◽  
Jens Meiler ◽  
Edward W. Lowe

Author(s):  
Khaled H. Barakat ◽  
Jonathan Y. Mane ◽  
Jack A. Tuszynski

Virtual screening, or VS, is emerging as a valuable tool in discovering new candidate inhibitors for many biologically relevant targets including the many chemotherapeutic targets that play key roles in cell signaling pathways. However, despite the great advances made in the field thus far, VS is still in constant development with a relatively low success rate that needs to be improved by parallel experimental validation methods. This chapter reviews the recent advances in VS, focusing on the range and type of computational methods and their successful applications in drug discovery. The chapter also discusses both the advantages and limitations of the various techniques used in VS and outlines a number of future directions in which the field may progress.


Author(s):  
Ammu Prasanna Kumar ◽  
Chandra S Verma ◽  
Suryani Lukman

Abstract Rab proteins represent the largest family of the Rab superfamily guanosine triphosphatase (GTPase). Aberrant human Rab proteins are associated with multiple diseases, including cancers and neurological disorders. Rab subfamily members display subtle conformational variations that render specificity in their physiological functions and can be targeted for subfamily-specific drug design. However, drug discovery efforts have not focused much on targeting Rab allosteric non-nucleotide binding sites which are subjected to less evolutionary pressures to be conserved, hence are likely to offer subfamily specificity and may be less prone to undesirable off-target interactions and side effects. To discover druggable allosteric binding sites, Rab structural dynamics need to be first incorporated using multiple experimentally and computationally obtained structures. The high-dimensional structural data may necessitate feature extraction methods to identify manageable representative structures for subsequent analyses. We have detailed state-of-the-art computational methods to (i) identify binding sites using data on sequence, shape, energy, etc., (ii) determine the allosteric nature of these binding sites based on structural ensembles, residue networks and correlated motions and (iii) identify small molecule binders through structure- and ligand-based virtual screening. To benefit future studies for targeting Rab allosteric sites, we herein detail a refined workflow comprising multiple available computational methods, which have been successfully used alone or in combinations. This workflow is also applicable for drug discovery efforts targeting other medically important proteins. Depending on the structural dynamics of proteins of interest, researchers can select suitable strategies for allosteric drug discovery and design, from the resources of computational methods and tools enlisted in the workflow.


2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Seyedeh Zahra Sajadi ◽  
Mohammad Ali Zare Chahooki ◽  
Sajjad Gharaghani ◽  
Karim Abbasi

Abstract Background Drug–target interaction (DTI) plays a vital role in drug discovery. Identifying drug–target interactions related to wet-lab experiments are costly, laborious, and time-consuming. Therefore, computational methods to predict drug–target interactions are an essential task in the drug discovery process. Meanwhile, computational methods can reduce search space by proposing potential drugs already validated on wet-lab experiments. Recently, deep learning-based methods in drug-target interaction prediction have gotten more attention. Traditionally, DTI prediction methods' performance heavily depends on additional information, such as protein sequence and molecular structure of the drug, as well as deep supervised learning. Results This paper proposes a method based on deep unsupervised learning for drug-target interaction prediction called AutoDTI++. The proposed method includes three steps. The first step is to pre-process the interaction matrix. Since the interaction matrix is sparse, we solved the sparsity of the interaction matrix with drug fingerprints. Then, in the second step, the AutoDTI approach is introduced. In the third step, we post-preprocess the output of the AutoDTI model. Conclusions Experimental results have shown that we were able to improve the prediction performance. To this end, the proposed method has been compared to other algorithms using the same reference datasets. The proposed method indicates that the experimental results of running five repetitions of tenfold cross-validation on golden standard datasets (Nuclear Receptors, GPCRs, Ion channels, and Enzymes) achieve good performance with high accuracy.


2020 ◽  
Vol 1 (supplement) ◽  
pp. 6
Author(s):  
Syed Babar Jamal ◽  
Shumaila Naz ◽  
Raees Khan ◽  
Adnan Haider ◽  
Rabail Zehra Raza ◽  
...  

SARS-CoV2 has affected millions of people around the globe with hundreds of mortalities. The emergence of SARS-COV2 is very recent, and there is no potential drug or vaccine available. In this review, we have compiled the most frequently used computational methods in drug discovery, target proteins of SARS-CoV2 as well as implementation of computational methods. Most recent literature on SARS-CoV2 has been compiled from various journal search engines including Google Scholar, Academia, PubMed, Scopus, Research Gate, and the Web of Science. The keywords chosen for the searches were COVID-19, Corona Virus, SARS-CoV2, drug development and future directions. This review has far reaching implications to both the public health and pharmaceutical industries for potential novel drug development against SARS-CoV2.


Sign in / Sign up

Export Citation Format

Share Document